Home›Stock Screener›Beta Drugs›Intrinsic Value

Beta Drugs Intrinsic Value

Beta Drugs intrinsic value. Beta Drugs (BETA) median intrinsic value is ₹1025.26 from 9 valuation models (range ₹490–₹1460), vs current price ₹1764.20 — -41.9% downside (Trading Above Calculated Value), margin of safety -72.1%. Analyse BETA promoter holding to track promoter, FII and institutional holdings.

Market Price (CMP)
₹1764.20
Primary Intrinsic Value
₹1459.92
Market Cap
₹1764 Cr
-41.9% Downside
Median Value
₹1025.26
Value Range
₹490 - ₹1460
Assessment
Trading Above Calculated Value
Safety Margin
-72.1%

BETA Valuation Methods Summary — DCF, Graham Number & P/E

Beta Drugs intrinsic value across 9 models vs current price ₹1764.20 — upside/downside and value range per method. Browse BETA annual financials for revenue, profit, balance sheet and cash flow data.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹1459.92 ₹1167.94 - ₹1751.90 -17.2% EPS: ₹66.36, Sector P/E: 22x
Book Value Method asset ₹490.00 ₹441.00 - ₹539.00 -72.2% Book Value/Share: ₹245.00, P/B: 2.0x
Revenue Multiple Method revenue ₹1112.00 ₹1000.80 - ₹1223.20 -37.0% Revenue/Share: ₹556.00, P/S: 2.0x
EBITDA Multiple Method earnings ₹1280.00 ₹1152.00 - ₹1408.00 -27.4% EBITDA: ₹128.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹705.68 ₹564.54 - ₹846.82 -60.0% CF Growth: 15.0%, Discount: 15%
PEG Ratio Method growth ₹529.26 ₹476.33 - ₹582.19 -70.0% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹1025.26 ₹922.73 - ₹1127.79 -41.9% Revenue Growth: 6.0%, Adj P/E: 15.5x
ROE Based Valuation profitability ₹1216.00 ₹1094.40 - ₹1337.60 -31.1% ROE: 31.0%, P/E Multiple: 16x
Graham Defensive Method conservative ₹529.26 ₹476.33 - ₹582.19 -70.0% EPS: ₹66.36, BVPS: ₹245.00
Method Types: Earnings Asset DCF Growth Dividend Conservative

BETA Intrinsic Value vs Market Price — All Valuation Models

Beta Drugs fair value range ₹490–₹1460 vs current market price ₹1764.20 across 9 valuation models. For current market price and key ratios, visit BETA share price screener.

BETA Intrinsic Value Analysis — Undervalued or Overvalued?

Beta Drugs median intrinsic value ₹1025.26, current price ₹1764.20 — Trading Above Calculated Value by 41.9%, margin of safety -72.1%.

What is the intrinsic value of BETA?

Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Beta Drugs (BETA) is ₹1025.26 (median value). With the current market price of ₹1764.20, this represents a -41.9% variance from our estimated fair value.

The valuation range spans from ₹490.00 to ₹1459.92, indicating ₹490.00 - ₹1459.92.

Is BETA undervalued or overvalued?

Based on our multi-method analysis, Beta Drugs (BETA) appears to be trading above calculated value by approximately 41.9%.

BETA Financial Health — Key Ratios vs Industry Benchmarks

Beta Drugs financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Return on Equity 31.0% Industry Standard: 15%+ Above 15% Measures shareholder return efficiency
Operating Margin 22.0% Industry Standard: 20%+ Above 20% Indicates operational efficiency level
Asset Turnover Ratio 1.12x Industry Standard: 1.0x+ Above 1.0x Measures asset utilization efficiency

BETA Cash Flow Quality — Operating & Free Cash Flow

Beta Drugs operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2025 ₹36 Cr ₹18 Cr Positive Free Cash Flow 7/10
March 2024 ₹31 Cr ₹24 Cr Positive Free Cash Flow 8/10
March 2023 ₹23 Cr ₹14 Cr Positive Free Cash Flow 8/10
March 2022 ₹30 Cr ₹19 Cr Positive Free Cash Flow 8/10
March 2021 ₹19 Cr ₹16 Cr Positive Free Cash Flow 8/10